About
- About Shionogi
Sustainability
- Sustainability
Innovation
- Innovation
News

Investors
Careers
Contact

Europe

Home
News
Press Releases
2024
10
Shionogi Announces Global Phase 3 Trial Demonstrates Post-Exposure Prophylactic Use of Ensitrelvir Prevents Symptomatic COVID-19

Release

Medical News

2024/10/29

Shionogi Announces Global Phase 3 Trial Demonstrates Post-Exposure Prophylactic Use of Ensitrelvir Prevents Symptomatic COVID-19

About
Sustainability
Innovation
Investors
News
Careers

Worldwide
Report Side Effect
Terms of Use
Cookie Policy
Contact Us
Sitemap
Privacy Policy
References

© Shionogi B.V. 2024. All rights reserved. This website is owned by Shionogi B.V. Registered with the Trade Register of the Dutch Chamber of Commerce under number 73229180. Registered address is Herengracht 464, 1017 CA, Amsterdam, the Netherlands.